


CLAIMS


1. A compound of Formula I including its stereoisomers, pharmaceutically acceptable salts, and hydrates thereof,




I


where:

- X and Y are independently selected from halogen, hydroxymethyl, and acetoxymethyl;
- R¹ is selected from C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl, C₃₋₇cycloalkyl,



C₅₋₇cycloalkenyl, -(CH₂)₁₋₆CO₂R³, and -(CH₂)_n  ;

R² is selected from hydrogen, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkylcarbonyl, CONHR³,



and

- R³ is selected from hydrogen and C₁₋₆alkyl;
- R⁴, R⁵, and R⁶ are independently selected from hydrogen, C₁₋₆alkyl, and C₁₋₆alkoxy;
- m is 0 or an integer from 1 to 6; and
- n is 0 or an integer from 1 to 6.

2. A compound of claim 1 wherein R³ is methyl, the carbon to which R³ is attached is of the (R) configuration, and m is 0.

3. A compound of claim 1 where R^1 is C_{1-6} alkyl, C_{3-6} alkenyl, or C_{3-6} alkynyl.
4. A compound of claim 2 where R^1 is C_{1-6} alkyl, C_{3-6} alkenyl, or C_{3-6} alkynyl.
5. A compound of claim 2 selected from the following group:
 - N-(2,5-dichlorophenyl)-N-(4-hydroxy-1-hexyn-5-yl)-4-chlorobenzenesulfonamide;
 - N-(2-fluoro-5-chlorophenyl)-N-(4-hydroxy-1-hexyn-5-yl)-4-chlorobenzenesulfonamide;
 - N-(2-fluoro-5-chlorophenyl)-N-(4-hydroxy-1-hexen-5-yl)-4-chlorobenzenesulfonamide;
 - N-(2-fluoro-5-chlorophenyl)-N-(3-hydroxyhex-2-yl)-4-chlorobenzenesulfonamide; and
 - N-(2-hydroxymethyl-5-chlorophenyl)-N-(2-(N-3-(1-imidazolyl)prop-1-yl-carbamoyl)but-3-yl)-4-chlorobenzenesulfonamide.
6. A compound of claim 1 wherein R^3 is methyl, the carbon to which R^3 is attached is of the (R) configuration, and m is 1.
7. A pharmaceutical composition for the treatment of disorders responsive to the inhibition of β -amyloid peptide production wherein the composition comprises a therapeutically effective amount of a compound of claim 1 in association with a pharmaceutically acceptable carrier or diluent.
8. A pharmaceutical composition of claim 7 suitable for oral administration.
9. A method for the treatment of disorders responsive to the inhibition of β -amyloid peptide production in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of claim 1.

10. A method of claim 9 wherein said disorder is Alzheimer's Disease and Down's Syndrome.